Research programme: amyotrophic lateral sclerosis therapeutics - SK biopharmaceuticalsAlternative Names: TDP-43 inhibitors - SK biopharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator SK biopharmaceuticals
- Mechanism of Action TDP-43 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in South Korea
- 19 Sep 2011 Early research in Amyotrophic lateral sclerosis in South Korea (unspecified route)